Imatinib alone and in combination for chronic myeloid leukemia
BJ Druker - Seminars in hematology, 2003 - Elsevier
Imatinib mesylate (STI571, Gleevec, Glivec; Novartis, Basel, Switzerland) has profoundly
changed the management of chronic myeloid leukemia (CML). The unprecedented efficacy
of a drug that specifically acts on the causative lesion in a malignant disorder is a proof of
principle for the concept of molecular targeted therapy. This article will review the
development of imatinib as a new therapy for CML. Data regarding the use of higher than
the standard dose of 400 mg of imatinib and combinations of imatinib with other …
changed the management of chronic myeloid leukemia (CML). The unprecedented efficacy
of a drug that specifically acts on the causative lesion in a malignant disorder is a proof of
principle for the concept of molecular targeted therapy. This article will review the
development of imatinib as a new therapy for CML. Data regarding the use of higher than
the standard dose of 400 mg of imatinib and combinations of imatinib with other …